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Objectives
To compare quality-of-life (QoL) outcomes at 6 months between
men with advanced prostate cancer receiving either transdermal
oestradiol (tE2) or luteinising hormone-releasing hormone
agonists (LHRHa) for androgen-deprivation therapy (ADT).
Patients and methods
Men with locally advanced or metastatic prostate cancer
participating in an ongoing randomised, multicentre UK trial
comparing tE2 versus LHRHa for ADT were enrolled into a QoL
sub-study. tE2 was delivered via three or four transcutaneous
patches containing oestradiol 100 lg/24 h. LHRHa was
administered as per local practice. Patients completed
questionnaires based on the European Organisation for Research
and Treatment of Cancer quality of life questionnaire 30-item
core (EORTC QLQ-C30) with prostate-speciﬁc module QLQ
PR25. The primary outcome measure was global QoL score at
6 months, compared between randomised arms.
Results
In all, 727 men were enrolled between August 2007 and October
2015 (412 tE2, 315 LHRHa) with QoL questionnaires completed
at both baseline and 6 months. Baseline clinical characteristics
were similar between arms: median (interquartile range) age of 74
(68–79) years and PSA level of 44 (19–119) ng/mL, and 40%
(294/727) had metastatic disease. At 6 months, patients on tE2
reported higher global QoL than those on LHRHa (mean
difference +4.2, 95% conﬁdence interval 1.2–7.1; P = 0.006), less
fatigue, and improved physical function. Men in the tE2 arm
were less likely to experience hot ﬂushes (8% vs 46%), and report
a lack of sexual interest (59% vs 74%) and sexual activity, but had
higher rates of signiﬁcant gynaecomastia (37% vs 5%). The higher
incidence of hot ﬂushes among LHRHa patients appear to
account for both the reduced global QoL and increased fatigue in
the LHRHa arm compared to the tE2 arm.
Conclusion
Patients receiving tE2 for ADT had better 6-month self-
reported QoL outcomes compared to those on LHRHa, but
increased likelihood of gynaecomastia. The ongoing trial will
evaluate clinical efﬁcacy and longer term QoL. These ﬁndings
are also potentially relevant for short-term neoadjuvant ADT.
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Introduction
Prostate cancer is the most frequent cancer diagnosis in
men in the developed world and responsible for 11 000
deaths per year in the UK and 26 000 in the USA [1,2].
Prostate cancer cell growth is driven by androgen
signalling, and androgen-deprivation therapy (ADT) forms
a cornerstone of treatment. Evidence supports the use of
ADT in conjunction with radiotherapy in localised [3,4]
and locally-advanced disease [5,6], and as ﬁrst-line therapy
in the metastatic setting [7].
ADT, usually achieved using LHRH agonists (LHRHa) in
contemporary practice, is associated with numerous side-
effects [8,9]. Speciﬁcally, these include declining bone health
[10,11], weight gain and metabolic syndrome [12], sexual
dysfunction [13–15], hot ﬂushes [16,17], mental and
cognitive decline [18–22], and physical deterioration and
fatigue [23–26]. LHRHa increase the risk of depression in
men with prostate cancer [14], reportedly driven by the
loss of sexual function [27]. Recent data suggest an
increased risk of subsequent Alzheimer’s disease [28]. An
association with increased cardiac events is described but
remains controversial [29]. Whereas a number of
interventions have been shown to ameliorate the toxicities
of LHRHa to a greater or lesser extent [8], further efforts
are required to maintain the highest possible quality of life
(QoL) for these patients.
PATCH (Prostate Adenocarcinoma: TransCutaneous
Hormones, MRC PR09) is an ongoing randomised
controlled trial comparing transdermal oestradiol (tE2)
delivered via transcutaneous patches vs LHRHa in men
with advanced prostate cancer. LHRHa act through the
hypothalamic-pituitary axis to suppress testosterone
production by the testes. Endogenous E2 in men is derived
from testosterone through aromatase. Thus, it is also
suppressed by, and consequently contributes to, the toxicity
proﬁle of LHRHa [9]. Exogenous administration of E2
inhibits the hypothalamic-pituitary axis (thereby
suppressing testosterone) as well but maintains E2 levels
and hence mitigates some of the toxicity of LHRHa.
Administration of exogenous E2 via oral or i.v. routes is
associated with risk of thrombosis and adverse
cardiovascular events [30]. However, tE2 avoids the hepatic
ﬁrst-pass effects mediating these risks, as supported by
previous results from PATCH (254 patients) showing
similar rates of cardiovascular events in both tE2 and
LHRHa arms after a median follow-up of 19 months [31].
Among this initial cohort, castration rates were similar in
both arms.
In the present report, we compare QoL outcomes at
6 months from randomisation between the two hormonal
treatments, based on data available from ~700 patients.
Patients and Methods
The study design for the PATCH trial has previously been
described [31]. Brieﬂy, patients from participating UK centres
were eligible for recruitment if they had locally advanced or
metastatic prostate cancer, and a treatment plan for indeﬁnite
ADT in the metastatic setting or ≥3 years for locally
advanced disease. National regulatory and ethics committees
approved the protocol, and participating hospitals obtained
the appropriate local approvals. Participants provided written
informed consent.
Men were randomly allocated (in a 2:1 ratio before February
2011 and then 1:1) to receive tE2 or LHRHa (open-label).
This was done centrally according to a computer-based
minimisation algorithm with a random element (80%),
balanced for the following factors: disease stage, age, smoking
status, personal or family history of heart disease, which
LHRHa agent was to be used, PSA level, intent to give radical
radiotherapy, and centre.
Patients in the tE2 arm received, after a dose regimen change
in August 2007 [32], four FemSeven patches (oestradiol
100 lg/24 h), which were self-administered and changed
twice weekly during the ﬁrst 4 weeks. This was reduced to
three patches changed twice weekly, provided testosterone
levels were <1.7 nmol/L. LHRHa was administered as per
local practice.
QoL Data Collection
Patients received a speciﬁc patient information sheet for the
QoL study and provided separate consent to participate in
this component of the study. QoL information was collected
on paper questionnaires using the European Organisation for
Research and Treatment of Cancer quality of life
questionnaire 30-item core (EORTC QLQ-C30) and the
prostate-speciﬁc module QLQ-PR25. These were self-
completed by participants, who were instructed to record
responses without discussion with site staff, friends or
relatives. Data were collected before randomisation, then at 4,
8 and 12 weeks, and subsequently every 3 months up to
2 years after randomisation. The QLQ-C30 includes a range
of domains that are either multi-item scales or single-item
measures: a global health status/QoL scale, ﬁve function scales
(physical, role, emotional, cognitive, and social), three
symptom scales (fatigue, pain, and nausea and vomiting), and
six single items (dyspnoea, insomnia, appetite loss,
constipation, diarrhoea, and ﬁnancial difﬁculties). QLQ-PR25
contains 25 items designed to assess QoL in patients with
prostate cancer, including urinary, bowel and sexual
symptoms and functioning, and hormone-related symptoms.
The Independent Data Monitoring Committee (IDMC)
permitted release of the QoL data during the ﬁrst 6 months
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from randomisation for patients already enrolled whilst the
main trial continues.
Statistical Analysis
For each multi-item QoL domain (e.g. global QoL), a
summary score was derived according to the EORTC QLQ-
C30 scoring manual [33], with a range of 0–100. For
example, the summary global QoL score is a standardised
average of the patients’ scores from the questions ‘How would
you rate your overall health during the past week?’ and ‘How
would you rate your overall quality of life?’. These scores
were considered as continuous variables. A higher score
corresponds to improved outcomes for global QoL and
function scales, but indicates more symptoms (hence poorer
outcomes) for symptoms scales. Single-item domains (e.g.
sexual interest) were analysed based on reported responses on
the questionnaires (‘not at all’, ‘a little’, ‘quite a bit’, or ‘very
much’).
The primary outcome was global QoL score at 6 months, as
differences in hormone-related symptoms potentially
impacting on QoL were expected to be apparent by then
[17,20,25,26,31]. The following domains were secondary
outcomes: sexual interest, sexual activity, whether feeling less
masculine as result of illness or treatment, cognitive
functioning, physical functioning, fatigue, and selected
hormone-related symptoms of hot ﬂushes, gynaecomastia,
and weight gain. Gynaecomastia was reported as sore or
enlarged nipples or breasts.
Patients were considered to have baseline QoL data, if they
completed their ﬁrst QoL questionnaire either by the date of
randomisation or 1 week after, but before starting trial
treatment. Information on QoL outcomes at 6 months was
based on the questionnaire completed nearest to this time
point, within a  3-month window.
Multi-item QoL domains at 6 months were compared
between randomised arms using Tobit regression models (to
account for scores being bounded by 0 and 100) [34],
adjusting for baseline score. Single-item domains were
categorised according to pre-deﬁned binary outcomes for
comparison between arms (for ease of clinical interpretation);
for example, hot ﬂushes were analysed as ‘quite a bit’/’very
much’ vs ‘not at all’/’a little’. These were compared between
arms using logistic regression models, adjusting for baseline
response.
All models were further adjusted for the following pre-
deﬁned baseline factors: age, calendar year (partly to account
for the change in allocation ratio), smoking status, stage of
disease (M0/M1), and whether patient was newly diagnosed
or relapsing. All comparisons between arms were based on
the original allocated treatment, and included patients
randomised after the change in patch dose regimen [32] who
had data on the relevant QoL domains at both baseline and
6 months. A signiﬁcance level of 0.05 was chosen a priori,
without adjustment for multiple statistical testing. Additional
exploratory analyses were undertaken to investigate
associations between global QoL and other domains.
Statistical analyses were performed using Stata version 14
(Stata Corporation, College Station, TX, USA).
Results
Between 14 August 2007 and 5 October 2015, 875 men were
recruited under the revised patch dose regime, 480 allocated
to tE2 and 395 to LHRHa. Within the tE2 arm, 468 patients
enrolled on the QoL sub-study, of whom 412 (86% of 480)
completed QoL questionnaires at both baseline and 6 months.
For the LHRHa group, 385 participated in the QoL sub-
study, with 315 (80% of 395) having both baseline and
6-month QoL data available (Fig. 1). Baseline clinical
characteristics were similar between arms for the 727 patients
included in the 6-month QoL analyses (Table 1). The overall
median (interquartile range) age was 74 (68–79) years and
PSA level was 44 (19–119) ng/mL, and 40% (294/727) had
metastatic disease. There were no differences in baseline
global QoL by age or testosterone level, but men with T4
tumours had worse global QoL compared with other T-stages,
and patients with metastatic disease had worse baseline QoL
than M0 patients.
Rates of castration were equivalent between the LHRHa and
tE2 arms at both 3 and 6 months; the proportion of patients
with testosterone concentrations ≤1.7 nmol/L was 93.6% for
LHRHa and 93.7% for tE2 at 3 months, and 89.8% and
92.2% at 6 months, respectively.
At 6 months, global QoL declined from baseline in both arms
(Table 2), but to a lesser extent in the tE2 patients (mean
change 2.8) compared to those on LHRHa (5.0). The
estimated mean difference in 6-month global QoL between
arms was +4.2 (95% CI 1.2–7.1; P = 0.006) in favour of tE2.
There was no evidence that the treatment effect on global
QoL at 6 months differed by age (≤70 vs >70 years; test for
interaction P = 0.56).
In addition, there was less decline in physical function among
tE2 patients (mean change 2.8 vs 5.7), with a mean
difference in 6-month score of +5.8 (95% CI 2.8–8.8;
P < 0.001) between arms. In addition, tE2 patients had less
fatigue at 6 months, mean difference between arms 4.3
(95% CI 8.1 to 0.6; P = 0.02) favouring the patches.
However, there was no difference in reported decline in
cognitive function between arms.
Analysis of speciﬁc domains linked with testosterone
suppression (Table 3) showed that tE2 patients were less
likely than LHRHa patients to report having no interest in
sex [59% vs 74%; odds ratio (OR) 0.42, 95% CI 0.28–0.62;
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P < 0.001)] and being ‘not at all’ sexually active (78% vs 87%;
OR 0.51, 95% CI 0.32–0.82; P = 0.005). Interestingly, there
was weak evidence that the negative effect of LHRHa
compared to tE2 on interest in sex was more pronounced in
patients aged ≤70 years than those >70 years (t-test for
interaction P = 0.06).
The likelihood of experiencing ‘quite a bit’ or ‘very much’
hot ﬂushes was signiﬁcantly lower in the tE2 group (8% vs
46%; OR 0.10, 95% CI 0.07–0.16; P < 0.001). However, as
expected, patients in the tE2 arm were much more likely
to report ‘quite a bit’ or ‘very much’ gynaecomastia than
those receiving LHRHa (37% vs 5%; OR 12.70, 95% CI
7.14–22.60; P < 0.001). There was no difference between
arms in patients who reported feeling ‘quite a bit’ or ‘very
much less’ masculine (as a result of their illness or
treatment) or experiencing ‘quite a bit’ or ‘very much’
weight gain.
An association between hot ﬂushes and deterioration in
global QoL was seen in both arms at 6 months, with patients
who experienced more severe symptoms reporting lower
scores (Table 4, P < 0.001). The relationship between
gynaecomastia and global QoL was assessed in the tE2 arm
only, owing to few LHRHa patients reporting symptoms.
Gynaecomastia was associated with poorer global QoL at
875 patients randomised
Randomiseda
349 completed a
QoL questionnaire at
baselineb
315 completed
6-month QoL
questionnaire
385 participated in the 
QoL sub-study
468 participated in the 
QoL sub-study
395to LHRHa arm 480 to tE2 arm
308 included in the 
primary analysis of 
6-month global QoL
score
403 included in the 
primary analysis of 
6-month global QoL
score
7 missing global QoL score 
on baseline and/or 
6-month questionnaire
9 missing global QoL score 
on baseline and/or 
6-month questionnaire
36 completed their first QoL
questionnaire either :
• >7 days after 
randomisation (n=30) 
• or within 7 days but after 
starting trial treatment 
(n=6)
29 completed their first QoL
questionnaire either: 
• >7 days after 
randomisation (n=24)
• or within 7 days but after 
starting trial treatment 
(n=5)
412 completed  
6-month QoL
questionnaire
34 without 6-month QoL 
questionnaire:
• 25 not yet due 6-month 
follow-up visit
• 6 either died, lost to 
follow-up or withdrew 
before 6-month visitc
• 3 did not complete QoL
questionnaire at 6-month 
visit
10 did not participate in QoL
sub-study
12 did not participate in QoL
sub-study
27 without 6-month QoL
questionnaire:
• 16 not yet due 6-month 
follow-up visit
• 4 either died, lost to 
follow-up or withdrew 
before 6-month visitc
• 7 did not complete QoL
questionnaire at 6-month 
visit
439 completed a
QoL questionnaire at
baselineb
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of patient inclusion in the analysis of 6-month QoL data. aThe allocation ratio
was 1:2 LHRHa:tE2 before 21/02/2011 and 1:1 thereafter. bPatients were considered to have baseline QoL data if they had completed their ﬁrst QoL
questionnaire either by the date of randomisation or within 1 week after but before starting trial treatment. cAs overall survival is a co-primary outcome
measure in the ongoing trial, the number of patients who have died before completing 6-month QoL questionnaire is not provided.
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6 months (Table 5, P = 0.004), although the adverse effect
was only seen in patients reporting ‘very much’
gynaecomastia (corresponding to 8% of the group with data
available). Other QoL domains associated with lower global
QoL score were: poorer cognitive and physical function,
increased fatigue, weight gain, and feeling less masculine
(data not shown).
After accounting for hot ﬂushes, there was little difference in
the 6-month global QoL score between arms (estimated mean
difference comparing tE2 vs LHRHa 0.4, 95% CI 3.8 to
3.0; P = 0.80). In comparison, the difference between arms
remained after other QoL domains were individually adjusted
for (data not shown). This suggests a signiﬁcant component
of the effect of treatment arm on global QoL could
potentially be attributable to the higher incidence of hot
ﬂushes in LHRHa patients.
In addition, there was an association between severity of hot
ﬂushes and fatigue at 6 months in both arms (data not
shown), which may potentially account for the increased
fatigue in the LHRHa vs tE2 arm; after adjusting for hot
ﬂushes, there was little difference in the 6-month fatigue
score between arms (mean difference comparing tE2 vs
LHRHa 0.0, 95% CI 4.3 to 4.4; P = 0.98). Further post hoc
analyses showed a relationship between hot ﬂushes and sleep
disturbance within both arms; 72% (124/172) of patients
reporting ‘quite a bit’ or ‘very much’ hot ﬂushes had trouble
sleeping compared to 43% (232/534) of those with ‘not at all’
or ‘a little’ hot ﬂushes (P < 0.001, with similar results by
arm).
Patients experiencing gynaecomastia were more likely to
report feeling less masculine at 6 months, with 24% (36/148)
of men who reported ‘quite a bit’ or ‘very much’
gynaecomastia feeling ‘quite a bit’ or ‘very much’ less
masculine compared to 7% (17/247) of those reporting ‘not at
all’ or ‘a little’ gynaecomastia (P < 0.001). The protocol
explicitly allowed prophylactic breast bud radiotherapy and
5% of patients on tE2 received this treatment as opposed to
no patients on LHRHa. Two patients underwent surgical
treatment for gynaecomastia who were both on tE2,
corresponding to 0.4% (2/480) of the overall tE2 arm cohort
enrolled to date.
Discussion
In the present study, we found better overall QoL after
6 months of ADT with tE2 compared to LHRHa, as well as
less fatigue and improved physical function. While the
magnitude of the QoL effects was modest [35], some
additional differences are important to note. Men treated with
LHRHa were more likely to report lack of sexual interest
(74% vs 59%) and being not sexually active (87% vs 78%)
[20]. In addition, tE2 patients had lower rates of hot ﬂushes
but more gynaecomastia, consistent with earlier ﬁndings from
the trial [31].
Signiﬁcant hot ﬂushes were reported by 8% of men on tE2
compared to 44% of those on LHRHa. Interestingly, there
was a suggestion that hot ﬂushes mediated the treatment
effect on global QoL, potentially accounting for both the
reduced global QoL and increased fatigue in the LHRHa
compared to tE2 arm. Conversely, 37% men on tE2 reported
signiﬁcant gynaecomastia compared with 5% on LHRHa,
although gynaecomastia was only seen to adversely affect
global QoL if the patient reported ‘very much’ symptoms
(which corresponded to <10% of the tE2 cohort). It is
noteworthy that men may vary signiﬁcantly in how
bothersome gynaecomastia is on an individual basis [36]. In
addition, data from the main PATCH trial suggest no
association between E2 levels and clinical gynaecomastia (data
not shown).
Table 1 Patient characteristics for those with both baseline and 6-month
QoL questionnaires completed (727 patients).
Variable LHRHa tE2
Number of patients 315 412
Age (years) at randomisation
<70, n (%) 99 (31) 128 (31)
70–79, n (%) 146 (46) 202 (49)
≥80, n (%) 70 (22) 82 (20)
Median (IQR) 74 (67–79) 73 (68–79)
Metastatic disease, n (%) 133 (42) 161 (39)
Bone metastases (% of those
with metastatic disease), n (%)
120 (90) 148 (92)
PSA concentration (ng/mL)
<50, n (%) 173 (55) 214 (52)
50–<500, n (%) 121 (39) 163 (40)
≥500, n (%) 19 (6) 35 (9)
Median (IQR) 43 (22–115) 45 (18–119)
Tumour stage, n (%)
T0/1/2 19 (6) 27 (7)
T3 220 (70) 296 (72)
T4 52 (17) 64 (16)
TX 24 (8) 25 (6)
N category, n (%)
N0 118 (37) 145 (35)
N+ 87 (28) 102 (25)
NX 110 (35) 165 (40)
Gleason sum score, n (%)
4–6 28 (10) 28 (8)
7 89 (31) 137 (37)
8–10 171 (59) 207 (56)
Smoking status, n (%)
Never smoked 119 (38) 167 (41)
Previous smoker 162 (51) 204 (50)
Current smoker 34 (11) 41 (10)
WHO performance status, n (%)
Normal activity 209 (66) 293 (71)
Avoid strenuous activity 92 (29) 102 (25)
Up and about >50% 14 (4) 17 (4)
Year of randomisation, n (%)
2007/2008 30 (10) 69 (17)
2009/2010 40 (13) 75 (18)
2011/2012 141 (45) 156 (38)
2013/2015 104 (33) 112 (27)
IQR, interquartile range.
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LHRHa therapy can severely impact on physical well-being
and other QoL outcomes [14–16]. Hot ﬂushes, reported by
40–80% of men on LHRHa [17,37,38], are linked to sleep
disturbance and psychological distress [16,38]. In our present
study, patients with hot ﬂushes had more trouble sleeping,
which may account for the effect of hot ﬂushes on increased
fatigue and reduced QoL. tE2 appeared to be effective in
reducing the severity of hot ﬂushes in men on ADT in a
prior study, consistent with our present ﬁndings [39]. The
adverse effects of LHRHa on sexual outcomes, which can
have signiﬁcant psychological impact on both patients and
their partners, have also been well-documented [13–15]. Data
from men castrated for reasons other than prostate cancer
suggest exogenous oestrogen can help maintain sexual interest
[40,41]. Other potential beneﬁts of tE2 reported include
protective effects on cognition [42], although we did not ﬁnd
a difference in cognitive function between arms within our
present study, possibly because short-term outcomes were
analysed and/or limitations of the questionnaires used for
assessing the cognitive domain.
Several strategies have been investigated in an attempt to
mitigate the adverse effects LHRHa therapy [8]. Randomised
trials have shown some beneﬁt of medoxyprogesterone,
venlafaxine and gabapentin in reducing hot ﬂushes associated
with LHRHa, and exercise may improve levels of fatigue and
overall QoL [43–45]. Agents which can potentially preserve
bone health during treatment with LHRHa include
bisphosphonates, denosumab or toremiﬁne [8]. Importantly,
however, data from PATCH recently showed that patients on
tE2 avoid the loss in bone mineral density seen with LHRHa
administration [46]. The data presented here suggest tE2 as
an alternative to LHRHa might limit the requirement for
additional treatments to allay the side-effects of LHRHa over
and above bone health. Alternatively a low dose of tE2 in
addition to LHRHa could be investigated in the future as a
treatment for bothersome hot ﬂushes.
Alternatively, an intermittent approach to ADT has been
assessed for clinical efﬁcacy and potential QoL beneﬁts. In the
non-metastatic setting, intermittent ADT appears not to be
Table 2 QoL multi-item domains: scores at 6 months by treatment arm.*
Outcome Arm Number of
patients
Mean score at
baseline (95% CI)
Mean score at
6 months (95% CI)
Mean change in
6-month score from
baseline (95% CI)
Mean difference
in 6-month score
between
arms (95% CI)
P comparing
arms
Global
QoL score
LHRHa 308 75.1 (72.7, 77.4) 70.1 (67.7, 72.4) 5.0 (7.4, 2.7)
tE2 403 78.0 (76.1, 80.0) 75.2 (73.3, 77.2) 2.8 (4.7, 0.8) +4.2 (1.2, 7.1) 0.006
Cognitive
function
LHRHa 309 86.9 (84.8, 89.0) 82.8 (80.7, 84.9) 4.1 (6.2, 2.0)
tE2 403 87.5 (85.7, 89.3) 84.0 (82.2, 85.9) 3.5 (5.3, 1.6) +1.9 (1.8, 5.5) 0.32
Physical
function
LHRHa 307 87.6 (85.4, 89.8) 81.8 (79.6, 84.1) 5.7 (7.9, 3.5)
tE2 399 89.0 (87.2, 90.9) 86.2 (84.3, 88.1) 2.8 (4.7, 1.0) +5.8 (2.8, 8.8) <0.001
Fatigue LHRHa 304 18.9 (16.4, 21.4) 27.2 (24.7, 29.7) 8.3 (5.8, 10.8)
tE2 400 17.1 (14.8, 19.4) 23.0 (20.8, 25.3) 6.0 (3.7, 8.2) 4.3 (8.1, 0.6) 0.02
*For global QoL, cognitive function and physical function, a higher score corresponds to a better outcome. For fatigue, a higher score corresponds to more fatigue.
Table 3 QoL single-item domains: proportion of patients with pre-deﬁned outcomes at 6 months by treatment arm.
Outcome Arm Number of
patients
Number (%) of
patients with
outcome
at baseline
Number (%) of
patients with
outcome
at 6 months
OR (95% CI) P comparing
arms
Felt quite a
bit/very
much less
masculine
LHRHa 292 16 (5) 41 (14)
tE2 381 18 (5) 53 (14) 0.92 (0.57, 1.48) 0.73
Not at all
interested in sex
LHRHa 268 118 (44) 199 (74)
tE2 350 155 (44) 208 (59) 0.42 (0.28, 0.62) <0.001
Not at all
sexually active
LHRHa 266 168 (63) 231 (87)
tE2 348 214 (61) 271 (78) 0.51 (0.32, 0.82) 0.005
Quite a bit/very
much
gynaecomastia
LHRHa 293 4 (1) 14 (5)
tE2 386 2 (1) 144 (37) 12.70 (7.14, 22.60) <0.001
Quite a
bit/very much
hot ﬂushes
LHRHa 291 6 (2) 135 (46)
tE2 390 9 (2) 32 (8) 0.10 (0.07, 0.16) <0.001
Quite a bit/very
much weight gain
LHRHa 296 13 (4) 21 (7)
tE2 379 13 (3) 27 (7) 1.06 (0.56, 2.00) 0.87
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inferior to continuous therapy in terms of overall survival,
with some potential beneﬁts as regards hot ﬂushes, libido and
possibly fatigue, but not global health [47]. However, a
randomised trial by Hussain et al. [48] including 1535 men
with metastatic prostate cancer failed to show non-inferiority
for intermittent ADT based on overall survival. Although
small improvements were initially seen for sexual function
and mental health, older men assigned to intermittent ADT
had no apparent reduction in bone, endocrine, or cognitive
events and experienced an increased incidence of ischaemic
and thrombotic events [49].
It is increasingly apparent across a number of QoL domains
that there are important differences in the unintended
consequences of ADT depending upon the method chosen to
achieve castrate levels of testosterone [50,51]. Here, we have
shown that at 6 months of treatment, tE2 improves patients’
QoL in a number of domains compared to LHRHa, i.e. fewer
hot ﬂushes, less fatigue, improved physical functioning, sexual
interest and sexual activity, but at a cost of increased
incidences of gynaecomastia. This can be viewed in addition
to the beneﬁcial effects on tE2 on bone mineral density
previously reported within PATCH [46], also noting the lack
of any excess cardiovascular or thromboembolic effects from
tE2 [31]. From our present data, hot ﬂushes appear to
potentially account for the increased fatigue and reduced
global QoL among patients on LHRHa.
We acknowledge the relatively short-term outcomes assessed
and presented here. However, ADT is often used for periods
as short as 6 months when administered as neoadjuvant
therapy along with radiotherapy to treat localised disease. As
such, our present 6-month QoL data are clinically pertinent,
given short-term neoadjuvant ADT has been shown to be
associated with impaired QoL [52]. Further data from the
ongoing trial will inform whether the differences between
arms persist long term. Although it is premature to suggest a
fundamental change in practice when it comes to starting
patients on ADT, comprehensive analysis of comparative
efﬁcacy and toxicity within PATCH will allow men and their
partners to optimise treatment choices.
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Table 4 Global QoL score at 6 months in both treatment arms, by patients’ experience of hot ﬂushes.
Experienced
hot ﬂushes
at 6 months
LHRHa arm tE2 arm Mean difference in
6-month score
(95% CI), both
arms combined*
Number of
patients
(% of total)
Mean score
at 6 months
(95% CI)
Mean change
in 6-month
score from
baseline (95% CI)
Number of
patients
(% of total)
Mean score
at 6 months
(95% CI)
Mean change in
6-month score
from baseline
(95% CI)
Not at all 77 (26) 75.1 (70.4, 79.8) 0.9 (5.6, 3.9) 288 (73) 78.6 (76.4, 80.8) 1.8 (4.0, 0.4) Reference group
A little 83 (28) 74.0 (69.9, 78.1) 4.0 (8.1, 0.1) 75 (19) 65.1 (60.6, 69.6) 5.9 (10.4, 1.4) 6.8 (10.6, 3.1)
Quite a bit 92 (31) 65.6 (61.1, 70.1) 8.1 (12.6, 3.5) 23 (6) 67.4 (58.0, 76.7) 5.8 (15.1, 3.6) 10.4 (15.0, 5.9)
Very much 47 (16) 62.4 (56.6, 68.2) 7.6 (13.4, 1.9) 10 (3) 65.0 (52.7, 77.4) 2.5 (14.8, 9.9) 11.8 (17.6, 6.0)
P < 0.001
*Estimated from Tobit regression models, adjusted for treatment arms, baseline global QoL score and other pre-deﬁned baseline factors. There was no evidence that the effect of hot
ﬂushes on 6-month global QoL score differed by treatment arm (P for interaction = 0.20).
Table 5 Global QoL score at 6 months in the tE2 arm*, by whether patient reported to have experienced gynaecomastia.
Experienced
sore or
enlarged
nipples
or breasts
Number of
patients
(% of total)
Mean score
at baseline
(95% CI)
Mean score
at 6 months
(95% CI)
Mean change
in 6-month
score from
baseline (95% CI)
Mean difference
in 6-month
score† (95% CI)
Not at all 55 (14) 78.6 (73.0, 84.3) 73.3 (67.9, 78.7) 5.3 (10.7, 0.1) Reference group
A little 190 (49) 80.0 (77.2, 82.7) 78.0 (75.2, 80.9) 1.9 (4.8, 0.9) 4.8 (0.8, 10.4)
Quite a bit 114 (29) 74.4 (70.9, 78.0) 73.8 (70.5, 77.0) 0.7 (3.9, 2.6) 3.3 (2.7, 9.3)
Very much 32 (8) 74.5 (66.7, 82.2) 63.8 (56.1, 71.5) 10.7 (18.4, 3.0) 7.6 (15.6, 0.4)
P = 0.004
*This association was not assessed in the LHRHa arm owing to few patients reporting symptoms. †Estimated from Tobit regression models, adjusted for baseline global QoL score
and other pre-deﬁned baseline factors.
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